{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:19:34Z","timestamp":1788182374087,"version":"build-2803163510"},"reference-count":20,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp;amp; Disease"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may rarely coexist with malignancies such as lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>This case report presents the first documented use of ofatumumab, a fully human anti\u2010CD20 monoclonal antibody, in a 75\u2010year\u2010old female with acetylcholine receptor (AChR)\u2010antibody\u2010positive generalized MG (gMG) following lung adenocarcinoma resection. Initially diagnosed with ocular MG (MGFA Class I), the patient progressed to refractory gMG (MGFA Class IIIa) post\u2010thymectomy and tumor resection, unresponsive to corticosteroids, tacrolimus, and intravenous immunoglobulin. Due to persistent symptoms and steroid\u2010induced complications, subcutaneous ofatumumab (20\u2009mg on Days 1, 7, and 14) was administered off\u2010label. Rapid clinical improvement was observed, with Myasthenia Gravis Composite (MGC) and MG Activities of Daily Living (MG\u2010ADL) scores declining from 20 to 10 and 17 to 10, respectively, within weeks. Minimal manifestation status (MMS) was sustained for 2 years with intermittent ofatumumab re\u2010administration (triggered by CD19\/CD20\u2009+\u2009B\u2010cell reconstitution &gt;\u20091%), alongside no tumor recurrence or adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights ofatumumab's potential efficacy and safety in managing refractory gMG post\u2010cancer resection, possibly via robust B\u2010cell depletion and reduced immunogenicity. These findings advocate for targeted B\u2010cell therapies as a viable strategy in complex, refractory MG cases, particularly where conventional immunosuppressants pose oncological concerns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/iid3.70501","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:57:46Z","timestamp":1787147866000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ofatumumab Treatment for Refractory Generalized Myasthenia Gravis Post\u2010Lung Adenocarcinoma Resection: A Case Report and Mechanistic Insight"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1505-4283","authenticated-orcid":false,"given":"Xia","family":"Long","sequence":"first","affiliation":[{"name":"Department of Neurology Shenzhen Second People's Hospital Shenzhen Guangdong China"},{"name":"Department of Neurology The First Affiliated Hospital of Shenzhen University Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6094-6776","authenticated-orcid":false,"given":"Yanwen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology The First Affiliated Hospital of Shenzhen University Shenzhen Guangdong China"},{"name":"Shenzhen Institute of Translational Medicine Shenzhen Second People's Hospital Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-6585","authenticated-orcid":false,"given":"Juan","family":"Xiong","sequence":"additional","affiliation":[{"name":"School of Public Health Shenzhen University Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5979-6170","authenticated-orcid":false,"given":"Wenfeng","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Pathology Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4084-2362","authenticated-orcid":false,"given":"Jinhua","family":"Qiu","sequence":"additional","affiliation":[{"name":"Huizhou First Hospital The First Huizhou Affiliated Hospital of Guangdong Medical University Huizhou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8617-7485","authenticated-orcid":false,"given":"Yanxia","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology Shenzhen Second People's Hospital Shenzhen Guangdong China"},{"name":"Department of Neurology The First Affiliated Hospital of Shenzhen University Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"e_1_2_11_2_1","first-page":"2492","article-title":"Evolution of Myasthenia Gravis Treatment Strategies and Individualized Treatment Strategies","volume":"101","author":"Li H. F.","year":"2021","journal-title":"Chinese Medical Journal (Beijing)"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.7599.1"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-018-0027-x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94263"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902832679"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009294"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semtcvs.2018.02.027"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2008.04.070"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3912376"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.12.3872"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1017"},{"key":"e_1_2_11_15_1","article-title":"Azathioprine for Multiple Sclerosis","volume":"2007","author":"CasettaI","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-52001-2.00022-4"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08966.x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000683"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/2055217316672100"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102210"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003331"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.70501","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/iid3.70501","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.70501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:46:54Z","timestamp":1788180414000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.70501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/iid3.70501"],"URL":"https:\/\/doi.org\/10.1002\/iid3.70501","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"value":"2050-4527","type":"print"},{"value":"2050-4527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2025-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70501"}}